Free Trial
NASDAQ:AARD

Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Aardvark Therapeutics logo
$10.50 +0.49 (+4.90%)
As of 05/23/2025 04:00 PM Eastern

About Aardvark Therapeutics Stock (NASDAQ:AARD)

Key Stats

Today's Range
$9.67
$10.81
50-Day Range
$7.00
$12.86
52-Week Range
$4.88
$19.58
Volume
22,053 shs
Average Volume
112,131 shs
Market Capitalization
$227.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.25
Consensus Rating
Buy

Company Overview

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Receive AARD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AARD Stock News Headlines

Cantor Fitzgerald Analysts Raise Earnings Estimates for AARD
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

AARD Stock Analysis - Frequently Asked Questions

Aardvark Therapeutics' stock was trading at $13.30 at the start of the year. Since then, AARD shares have decreased by 21.1% and is now trading at $10.50.
View the best growth stocks for 2025 here
.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) issued its earnings results on Wednesday, May, 14th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.

Aardvark Therapeutics (AARD) raised $100 million in an IPO on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets acted as the underwriters for the IPO.

Aardvark Therapeutics' top institutional investors include Decheng Capital LLC (18.06%), Cormorant Asset Management LP (3.69%), Braidwell LP (2.30%) and Adage Capital Partners GP L.L.C. (1.15%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends
.

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
5/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AARD
Previous Symbol
NASDAQ:AARD
Web
N/A
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.25
High Stock Price Target
$50.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+197.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$227.81 million
Optionable
N/A
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:AARD) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners